Interferon in the treatment of cutaneous T-cell lymphoma.
Interferon in the treatment of cutaneous T-cell lymphoma.
复制标题
DOI：
10.1111/j.1396-0296.2003.01643.x
复制
发表时间：
2003-01-01
影响因子：
3.6
通讯作者：
Olsen, Elise A
中科院分区：
文献类型：
--
作者：
Olsen, Elise A
干扰素是一种具有广泛体内效应的多肽，在皮肤t细胞淋巴瘤（CTCL）中已显示出疗效。特别有用的是α干扰素（IFN），作为单一药物，已显示>部分缓解率为50%，>完全缓解率为20%。副作用是可预测的，通常耐受性良好且与剂量相关。IFN的疗效随着联合治疗而增加，而伴随的副作用没有显著增加。本文介绍了不同IFN亚型的具体情况，其固有的生物活性，药代动力学，CTCL的疗效和安全性。
Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.